Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.490
+0.080 (2.35%)
At close: Dec 20, 2024, 4:00 PM
3.500
+0.010 (0.29%)
After-hours: Dec 20, 2024, 6:38 PM EST
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for XERS stock have an average target of 4.87, with a low estimate of 3.00 and a high estimate of 6.60. The average target predicts an increase of 39.54% from the current stock price of 3.49.
Analyst Consensus: Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for XERS stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $6.6 | Strong Buy | Maintains | $6 → $6.6 | +89.11% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $3 | Buy → Hold | Downgrades | $3 | -14.04% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +71.92% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +71.92% | May 31, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | -14.04% | May 10, 2024 |
Financial Forecast
Revenue This Year
203.69M
from 163.91M
Increased by 24.27%
Revenue Next Year
241.52M
from 203.69M
Increased by 18.57%
EPS This Year
-0.42
from -0.45
EPS Next Year
-0.23
from -0.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 211.1M | 273.0M | 341.7M | |||
| Avg | 203.7M | 241.5M | 289.0M | |||
| Low | 194.9M | 213.7M | 241.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 28.8% | 34.0% | 41.5% | |||
| Avg | 24.3% | 18.6% | 19.7% | |||
| Low | 18.9% | 4.9% | 0.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.40 | -0.05 | 0.21 | |||
| Avg | -0.42 | -0.23 | 0.05 | |||
| Low | -0.44 | -0.29 | -0.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.